This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Rebecca Voelker

JAMA. 2000;284:2863.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The worldwide supply of antiparasitic drugs appears to be dwindling because markets where the drugs most commonly are used are not economically viable, according to researchers who spoke at the recent American Society of Tropical Medicine and Hygiene meeting in Houston.

"Parasites are a very common cause of disease in the world, but because there is no market for antiparasitic drugs, drug companies are discontinuing production," said A. Clayton White, Jr, MD, of Baylor College of Medicine in Houston. White's "no market" reference means that parasitic diseases occur most often in developing countries that cannot afford to support production of the drugs.

White and a colleague from the US Centers for Disease Control and Prevention (CDC) reported that US production of praziquantel, used to treat schistosomiasis, had been halted because the drug isn't profitable. Bithionol, which is used to treat liver fluke infections, is available only through the . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?